Targeting IRES-Mediated p53 Synthesis for Cancer Diagnosis and Therapeutics

被引：20

作者：

Ji, Bai ^{[1
,2
]}

Harris, Benjamin R. E. ^{[2
]}

Liu, Yahui ^{[1
]}

Deng, Yibin ^{[2
,3
]}

Gradilone, Sergio A. ^{[2
,3
]}

Cleary, Margot P. ^{[2
,3
]}

Liu, Jianhua ^{[1
]}

Yang, Da-Qing ^{[2
,3
]}

机构：

[1] Jilin Univ, Hosp 1, Dept Hepatobiliary & Pancreat Surg, Changchun 130021, Peoples R China

[2] Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA

[3] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2017年 / 18卷 / 01期

关键词：

p53; internal ribosome entry site (IRES); DNA damage; IRES-trans acting factors (ITAFs); MESSENGER-RNA TRANSLATION; INITIATION-FACTOR EIF4E; RIBOSOME ENTRY SITES; DNA-DAMAGE; HELICASE-A; PROTEIN; MECHANISM; BREAST; BINDING; PARTICIPATION;

D O I：

10.3390/ijms18010093

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

While translational regulation of p53 by the internal ribosome entry site (IRES) at its 5'-untranslated region following DNA damage has been widely accepted, the detailed mechanism underlying the translational control of p53 by its IRES sequence is still poorly understood. In this review, we will focus on the latest progress in identifying novel regulatory proteins of the p53 IRES and in uncovering the functional connection between defective IRES-mediated p53 translation and tumorigenesis. We will also discuss how these findings may lead to a better understanding of the process of oncogenesis and open up new avenues for cancer diagnosis and therapeutics.

引用

页数：12

共 50 条

[31] Targeting mutant p53 for efficient cancer therapy
Vladimir J. N. Bykov
Sofi E. Eriksson
Julie Bianchi
Klas G. Wiman
Nature Reviews Cancer, 2018, 18 : 89 - 102
[32] Targeting Therapies for the p53 Protein in Cancer Treatments
Levine, Arnold J.
ANNUAL REVIEW OF CANCER BIOLOGY, VOL 3, 2019, 3 : 21 - 34
[33] Targeting mutant p53 in cancer: the latest insights
Silvia Di Agostino
Giulia Fontemaggi
Sabrina Strano
Giovanni Blandino
Gabriella D’Orazi
Journal of Experimental & Clinical Cancer Research, 38
[34] Strategies for therapeutic targeting of the p53 pathway in cancer
Wiman, K. G.
CELL DEATH AND DIFFERENTIATION, 2006, 13 (06): : 921 - 926
[35] Targeting cancer stem cells with p53 modulators
Zhang, Zhan
Liu, Ling
Gomez-Casal, Roberto
Wang, Xinhui
Hayashi, Ryo
Appella, Ettore
Kopelovich, Levy
DeLeo, Albert B.
ONCOTARGET, 2016, 7 (29) : 45079 - 45093
[36] Strategies for therapeutic targeting of the p53 pathway in cancer
K G Wiman
Cell Death & Differentiation, 2006, 13 : 921 - 926
[37] Targeting Oncogenic Mutant p53 for Cancer Therapy
Parrales, Alejandro
Iwakuma, Tomoo
FRONTIERS IN ONCOLOGY, 2015, 5
[38] p53 as a therapeutic target: unresolved issues on the road to cancer therapy targeting mutant p53
Fojo, T
DRUG RESISTANCE UPDATES, 2002, 5 (05) : 209 - 216
[39] Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-κB pathways
Anwesha Dey
Vinay Tergaonkar
David P. Lane
Nature Reviews Drug Discovery, 2008, 7 : 1031 - 1040
[40] Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-κB pathways
Dey, Anwesha
Tergaonkar, Vinay
Lane, David P.
NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (12) : 1031 - 1040

← 1 2 3 4 5 →